Integrative Network Modeling Approaches to Precision Cancer Medicine: Back to the Future

Needs Statement

Physicians, residents, fellows, scientists, and other health professionals in general practice specialties such as internal medicine, oncology, surgery, and pathology need to be updated about the practice and implementation of precision medicine initiatives to improve the delivery of targeted and individualized care. Health professionals should be aware of the ethical issues that arise in the practice of precision medicine. Testing for genetically influenced diseases can affect personalized management of individuals and their families.

Educational Objectives

At the conclusion of the session, the participants should be able to:

• Summarize a general overview of the rich sources of information to identify variations in signaling pathways.
• Explain existing and new tools for pathway-based differential network analysis.
• Outline a general framework and new tool for pan-cancer network modeling.

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Director

Christopher Amos, Ph.D.

Director

Institute of Clinical and Translational Medicine

Baylor College of Medicine

Houston, Texas

Disclosure: Nothing to disclose.

Term of Approval

September 2019 through September 2021. Original release date: September 2019

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.